Search PubMed⌕ Search

Biomedical subjects

Z Stelmasiak

Publications and source records attributed to Z Stelmasiak.

108 records · Page 6Linked to original sources
PubMedDate not supplied

[Tryptophan and tyrosine in blood and cerebrospinal fluid in patients with recent cerebral infarct].

The determinations were carried out in the blood and cerebrospinal fluid of 40 patients with recent cerebral infarction and 30 controls. Tryptophan concentration was determined by the fluorimetric method of Denckla and Dewey, and tyrosine concentration by the method of Waalkes and Udenfried. A statistically significant rise of free tryptophan concentration in the plasma and tryptophan concentration in the cerebrospinal fluid was found which seemed to depend on the stress reaction following brain infarction. No statistically significant changes were observed in the concentration of tyrosine in the cerebrospinal fluid and plasma in patients with brain infarction.

Adult↗
PubMedDate not supplied

[Case of arteriovenous hemangioma, aneurysm and subdural hematoma].

In a woman aged 53 years angiography of the internal carotid arteries demonstrated presence of an aneurysm in the region of arteriovenous fistula, which is a very rare occurrence, and coexistence of bilateral spontaneous subdural heamatomas. This coincidence has not been reported.

Cerebral Arteries↗
PubMedDate not supplied

[Glucose, pyruvate and lactate concentrations in the cerebrospinal fluid in patients with cerebral infarction].

The determinations were performed in cerebrospinal fluid of 50 patients with recent cerebral infarction in the 1-st, 3-rd and 10-th day of disease. Spectrophotometrie methods were used for the determination of lactate and pyruvate and a colorimetric method for glucose determination. A statistically significant increase of glucose in the cerebrospinal fluid on the 1-st day after cerebral infarction and of pyruvate, lactate and lactate: pyruvate index on 1-st and 3-rd day after cerebral infarction was found. The results obtained point to intensification of the anaerobic pathway of glucose metabolism.

Adult↗
PubMedDate not supplied

[Treatment of multiple sclerosis with cladribine (2-CDA), a new immunosuppressant agent. Theoretical basis and preliminary results].

The rationale for immunosuppressive treatment of multiple sclerosis comes from current concepts of pathogenesis of this disease. However, clinical effects of immunosuppression have been largely disappointing. Cladribine (chloro-2'-deoxyadenosine, 2CdA) is a new antileukaemic drug which also shows a strong immunosuppressive activity in vitro and in vivo. Being successfully used to treat lymphoproliferative diseases during last few years, cladribine is currently tested in multiple sclerosis. Preliminary results of two independent randomized, placebo-controlled trials are very promising. The indicate that treatment with cladribine may halt the progression of chronic progressive MS, and decrease the frequency of relapses and improve neurological status in remitting-relapsing stage of the disease.

Blood-Brain Barrier↗